Antibe Therapeutics is developing a badly-needed new class of anti-inflammatory and analgesic NSAIDs that seem to be much easier on the stomach. The FDA just approved the company's IND for otenaproxesul while the drug has already undergone Phase 2 trials in Canada and is gearing up for Phase 3. Not your typical path for drug development, but whatever works is just fine.
When I wrote about "Magic Aleve" -- a derivative of Aleve/naproxen that appears to be both G.I.-friendly and a more potent analgesic/antiinflammatory than Aleve itself -- a number of questions arose. Dr. John Wallace, CSO of Antibe, which is developing the drug called ATB-346, kindly agreed to answer them.
There hasn't been a material advance in the pharmacological treatment of pain since the 1890s, when heroin and aspirin were invented. That may change if an experimental drug being developed by a Toronto-based drug company keeps performing in advanced clinical trials. This could be huge.
There are three basic facts about death: (1) We all have to die. (2) All young deaths are tragic deaths. (3) Some of us die in ways that are more interesting than others, and those deaths often make their way into case reports. This story involves all three.
A major protein inside the egg, called ovalbumin, possesses the sulfur-containing amino acid cysteine. When heated, these sulfur atoms are converted to hydrogen sulfide, the nasty gas associated with rotten eggs and bodily functions. It doesn't take much to wrinkle our noses.